NCT06863844 The Evaluation of Molecular Markers From PRedittivI DNA of Clinical Outcomes in Patients With UROthelial Tumor
| NCT ID | NCT06863844 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Urothelial Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 210 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2025-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 210 participants in total. It began in 2023-03-01 with a primary completion date of 2025-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The genetic characterization of urothelial tumor disease has brought to light important information about the biology of the disease. The evaluation of molecular DNA markers on tumor tissue could be an approach able to provide important information on the possible aggressiveness of the disease and the sensitivity/resistance profile to drugs commonly adopted in the advanced stage. The main objective of this study is to identify specific molecular profiles from DNA capable of predicting the clinical course of the disease and the possible sensitivity/resistance of the disease to systemic treatments
Eligibility Criteria
Inclusion Criteria For the retrospective part: \- Patients diagnosed with locally advanced operated or metastatic urothelial cancer in follow-up or treatment Exclusion Criteria For the retrospective part: \- Deceased patients who have not already performed the NGS analysis from clinical practice. For the prospective part: Patients * aged \> 18 years * suffering from locally advanced or metastatic urothelial neoplasia * with the availability of tumor tissue obtained during surgery on a primary tumor or metastasis or during a diagnostic biopsy. Patients included in the study will also have to consciously express their willingness to participate in the study after signing the written informed consent.
Contact & Investigator
Francesco Massari, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06863844 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Urothelial Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06863844 currently recruiting?
Yes, NCT06863844 is actively recruiting participants. Contact the research team at francesco.massari@aosp.bo.it for enrollment information.
Where is the NCT06863844 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06863844 clinical trial?
NCT06863844 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Francesco Massari, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 210 participants.